To further validate the role of PARP1 in resistance to ATRi/CHK1i, we generated neoR-CRC-SCs from 6 additional CRC-SCs with moderate/high sensitivity to CHK1i. This evidence concerns the gene PARP1 and colorectal carcinoma.